251 related articles for article (PubMed ID: 35462487)
1. [Exploring the effects of entecavir treatment on the degree of liver fibrosis in patients with non-alcoholic fatty liver combined with chronic hepatitis B in Tibet region].
Wen QP; Qian H; Ba S; Lu MJ; Silang LDJ; Shi L
Zhonghua Gan Zang Bing Za Zhi; 2022 Mar; 30(3):304-308. PubMed ID: 35462487
[No Abstract] [Full Text] [Related]
2. [Analysis of efficacy and factors influencing sequential combination therapy with tenofovir alafenamide fumarate after treatment with entecavir in chronic hepatitis B patients with low-level viremia].
Liu LP; Wu XP; Cai TP; Wang L; Sun J; Liang JY; Ma SP; Gan X; Ruan NH; Ge SF
Zhonghua Gan Zang Bing Za Zhi; 2023 Feb; 31(2):118-125. PubMed ID: 37137825
[No Abstract] [Full Text] [Related]
3. Changes in APRI and FIB-4 in HBeAg-negative treatment-naive chronic hepatitis B patients with significant liver histological lesions receiving 5-year entecavir therapy.
Liu R; Guo J; Lu Y; Zhang L; Shen G; Wu S; Chang M; Hu L; Hao H; Li M; Xie Y
Clin Exp Med; 2019 Aug; 19(3):309-320. PubMed ID: 31111345
[TBL] [Abstract][Full Text] [Related]
4. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-21 Is Associated with Early Antiviral Response in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B and Nonalcoholic Fatty Liver Disease.
Liu X; Shen Z; Zhang H; Liang J; Lin H
J Interferon Cytokine Res; 2016 Jun; 36(6):367-73. PubMed ID: 26840345
[TBL] [Abstract][Full Text] [Related]
6. The effects of the insulin resistance index on the virologic response to entecavir in patients with HBeAg-positive chronic hepatitis B and nonalcoholic fatty liver disease.
Zhu LY; Wang YG; Wei LQ; Zhou J; Dai WJ; Zhang XY
Drug Des Devel Ther; 2016; 10():2739-44. PubMed ID: 27621595
[TBL] [Abstract][Full Text] [Related]
7. ALT Levels in Treatment-Naive, Chronic Hepatitis B Patients with Concurrent Fatty Liver Disease: A US Nationwide Study.
Chang CY; Kam L; Dang N; Cheung R; Nguyen MH
Dig Dis; 2022; 40(4):497-505. PubMed ID: 34348281
[TBL] [Abstract][Full Text] [Related]
8. [Evaluation of the efficacy of tenofovir disoproxil fumarate in the treatment of chronic hepatitis B combined with nonalcoholic fatty liver disease by high-sensitivity detection of HBV DNA levels].
Liang CG; Wang X; Liu SH; Shi XF
Zhonghua Gan Zang Bing Za Zhi; 2023 Feb; 31(2):113-117. PubMed ID: 37137824
[No Abstract] [Full Text] [Related]
9. [Predictive value of liver pathologic changes in determining the effectiveness of entecavir treatment for chronic hepatitis B-An analysis of 1 366 cases].
Sun MM; Zhang W; Chen G; An Y; Wang YQ; Shang QH
Zhonghua Yi Xue Za Zhi; 2017 Apr; 97(15):1160-1164. PubMed ID: 28427123
[No Abstract] [Full Text] [Related]
10. Cirrhosis has no impact on therapeutic responses of entecavir for chronic hepatitis B.
Wang PC; Wei TY; Tseng TC; Lin HH; Wang CC
Eur J Gastroenterol Hepatol; 2017 Aug; 29(8):946-950. PubMed ID: 28538267
[TBL] [Abstract][Full Text] [Related]
11. [Entecavir combined with Fufang Biejia Ruangan tablet in treatment of chronic hepatitis B patients with liver fibrosis: 96-week efficacy analyses].
Yang NH; Yuan GS; Zhou YC; Liu JW; Huang HP; Hu CG; Xiong L; Li Y; Zhou FY; Yang SL; Zhou YP
Nan Fang Yi Ke Da Xue Xue Bao; 2016 Jun; 36(6):775-9. PubMed ID: 27320877
[TBL] [Abstract][Full Text] [Related]
12. Fatty liver is not independently associated with the rates of complete response to oral antiviral therapy in chronic hepatitis B patients.
Li J; Le AK; Chaung KT; Henry L; Hoang JK; Cheung R; Nguyen MH
Liver Int; 2020 May; 40(5):1052-1061. PubMed ID: 32086988
[TBL] [Abstract][Full Text] [Related]
13. Management of individuals with chronic hepatitis B virus infection and persistent normal or mildly elevated aminotransferase levels.
Yan JY; Li ZQ; Yu ZJ; Kan QC
J Cell Biochem; 2019 Apr; 120(4):6632-6641. PubMed ID: 30368885
[TBL] [Abstract][Full Text] [Related]
14. Impact of nonalcoholic fatty liver disease status change on antiviral efficacy of nucleos(t)ide analogues in HBeAg-positive chronic hepatitis B.
Tang Y; Fan R; Lan Z; Xie Q; Zhang J; Liang X; Wang H; Tan D; Cheng J; Chen S; Ning Q; Bai X; Xu M; Chen X; Niu J; Shi J; Ren H; Gao Z; Wang M; Dou X; Hou J; Sun J
J Med Virol; 2023 Feb; 95(2):e28501. PubMed ID: 36655747
[TBL] [Abstract][Full Text] [Related]
15. [Analysis of clinical and pathological features of chronic hepatitis B combined with metabolic-associated fatty liver disease].
Shang MY; Chen YZ; Bao J; Tong YL
Zhonghua Gan Zang Bing Za Zhi; 2023 Feb; 31(2):126-132. PubMed ID: 37137826
[No Abstract] [Full Text] [Related]
16. Impact of Fuzheng Huayu tablet on antiviral effect of entecavir in patients with hepatitis B cirrhosis.
Cheng DY; Zhao ZM; Wan G; Zheng HW; Huang JQ; Liu CH; Xing HC
Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):479-484. PubMed ID: 35346577
[TBL] [Abstract][Full Text] [Related]
17. Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B.
Jin X; Chen YP; Yang YD; Li YM; Zheng L; Xu CQ
PLoS One; 2012; 7(3):e34198. PubMed ID: 22479562
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage.
Wu IC; Lai CL; Han SH; Han KH; Gordon SC; Chao YC; Tan CK; Sievert W; Tanwandee T; Xu D; Neo BL; Chang TT
Hepatology; 2010 Apr; 51(4):1185-9. PubMed ID: 20044806
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the efficacy of Biejia decoction pill combined with entecavir in the treatment of hepatitis B liver fibrosis/cirrhosis by VCTE.
Wan L; Hu C; Wang F; Xu K; Li F; He B; Wu Z; Luo L; Wen Z
Sci Rep; 2023 Nov; 13(1):19616. PubMed ID: 37949927
[TBL] [Abstract][Full Text] [Related]
20. Entecavir Combined With Adefovir Ameliorates Patients With Chronic Hepatitis B Who Fail to Respond to Nucleotide (Acid) Analog Monotherapy.
Li XY; You X; Jie YS; Lin GL; Wu YK; Huang MX; Zhang M; Li ZY; Xie DY; Gao ZL; Chong YT
Am J Ther; 2017 May; 24(3):e250-e258. PubMed ID: 25923228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
